ARQ197 HCC: Because Met+ patients typically have much worse OS outcome than Met- patients. This is not only true in HCC but also in NSCLC, see Roche MetMab trial. What Met inhibitor does is to bring Met+ patients OS inline with Met- patients. If you look at ARQ197 2nd line HCC ITT population, placebo arm MOS 6.2 months (generally I don't think anyone should look at MOS without HR because HR is more consistent), which is more inline with overall 2nd line HCC. What
Here is a discussion on MetMab and Tivantinib in NSCLC:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.